PAM
CLDX icon

Paradigm Asset Management’s Celldex Therapeutics CLDX Stock Holding History

Paradigm Asset Management’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-1,087
Closed -$411K – 810
2015
Q2 		$411K Hold
1,087
– – 0.05% 366
2015
Q1 		$454K Sell
1,087
-4,040
-79% -$1.45M 0.05% 348
2014
Q4 		$1.4M Buy
+5,127
New +$1.27M 0.18% 161

Other funds holding CLDX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CWAM
Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Paradigm Asset Management's CLDX Position: Q3 2015 in Review

Paradigm Asset Management sold out of Celldex Therapeutics (CLDX) in Q3 2015, closing a stake of 1,087 shares — an estimated $411K sold.

Paradigm Asset Management first reported a position in CLDX in Q4 2014 and held it in 3 quarters. The position peaked at $1.4M in Q4 2014. 162 funds tracked by Wall St. Rank hold CLDX as of Q3 2015.

  • Paradigm Asset Management reported no remaining Celldex Therapeutics position as of Q3 2015 after selling out during the quarter.
  • Paradigm Asset Management sold 1,087 Celldex Therapeutics shares in Q3 2015, an estimated $411K.
  • Paradigm Asset Management first reported a position in Celldex Therapeutics in Q4 2014 and held it in 3 quarters.
  • Paradigm Asset Management's Celldex Therapeutics position peaked at $1.4M in Q4 2014.
  • 162 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q3 2015.

Based on Paradigm Asset Management's 13F filing for Q3 2015, filed 13 Nov 2015.